Nelson Advisors 20 Future European HealthTech and MedTech Series 2026
- Nelson Advisors
- 3 minutes ago
- 17 min read
Nelson Advisors have researched 20 future Healthtech and MedTech leaders in 20 European countries, highlighting the founders, scientists and technologists building innovative solutions and companies. In addition to the 20 x 20 Series, we have also predicted 3 HealthTech and MedTech hubs across Europe with the potential to become centres of excellence.
Ghent, Porto, Wroclaw: Future European HealthTech and MedTech Hubs
The European medical technology and healthcare innovation landscape is currently traversing a period of profound structural realignment, characterised by a transition from speculative digital fragmentation toward a model of industrial maturity and regulatory rigor.
As the global MedTech market is projected to expand from a valuation of $549.5 Billion in 2025 to approximately $853.4 Billion by 2035, growing at a compound annual growth rate (CAGR) of 4.5%, the European theatre is emerging as a critical frontier for high-conviction investment and clinical validation. This transformation is driven by a convergence of high medical trend rates, which are expected to reach 11.68% globally in 2025, and a persistent workforce crisis that has seen burnout rates among medical staff climb to 63% in regions like Spain and 36% in France.
Consequently, three specific European hubs, Ghent in Belgium, Porto in Portugal, and Wroclaw in Poland are manifesting as primary centres of excellence, leveraging unique combinations of institutional heritage, sovereign funding and technological specialisations in robotics, genomic data and artificial intelligence (AI).
20 Future Slovakian HealthTech and MedTech Leaders
The Slovakian healthcare technology ecosystem has transitioned from a period of nascent development into a sophisticated phase of global integration and scientific leadership. This evolution is not a localised phenomenon but rather a strategic realignment of Central and Eastern Europe (CEE) as a hub for high-precision biotechnology and digital health.
At the heart of this transformation are 20 key individuals, founders, researchers and institutional leaders, whose work in artificial intelligence, molecular diagnostics and therapeutic platforms is redefining the boundaries of clinical medicine.
This report examines these leaders not merely as successful entrepreneurs but as the architects of a data-driven, patient-centric healthcare infrastructure that leverages Slovakia's deep academic heritage in biochemistry and engineering.
20 Future Hungarian HealthTech and MedTech Leaders
The landscape of Hungarian healthcare innovation has transitioned from a historical foundation of pharmaceutical excellence into a dynamic, multi-disciplinary ecosystem defined by medical deep tech, artificial intelligence and sophisticated biotechnology. This transformation is anchored by a strategic shift in the country’s academic and financial infrastructure, moving toward a "fourth-generation" research model where knowledge transfer and commercialization are prioritized alongside academic inquiry.
Between 2015 and 2025, over €925 million in venture capital flowed into the Hungarian startup ecosystem, with the life sciences sector, encompassing pharmaceuticals, biotechnology and MedTech, securing a significant portion of this investment.
This growth is not accidental but is the result of a coordinated effort by state agencies, university-led technology transfer centres and a new generation of scientists-turned-entrepreneurs who are bridging the gap between the laboratory bench and the patient's bedside.
20 Future Greek HealthTech and MedTech Leaders
The Greek innovation ecosystem has entered a period of structural maturation, characterised by a transition from nascent digital adoption to the creation of globally competitive deep-tech enterprises. As of 2025, the Greek startup ecosystem is valued at approximately $4.2 billion, with Athens emerging as a significant node in the global innovation network, ranking 120th worldwide and 26th in Western Europe.
This evolution is underpinned by the "Digital Transformation Bible 2020–2025," a foundational policy framework that has prioritised the modernisation of public health services through the deployment of "digital rails," such as the national e-Prescription system and the MyHealth mobile application operated by IDIKA S.A.. Furthermore, the 2024 National AI Strategy, "A Blueprint for Greece’s AI Transformation," has established a dedicated layer for artificial intelligence in healthcare, fostering an environment where scientific excellence from institutions like the Foundation for Research and Technology-Hellas (FORTH) and the National Centre for Scientific Research "Demokritos" can be commercialised effectively.
The financial engine driving this transformation is increasingly robust. In 2025, total capital raised by Greek startups exceeded €732 million, representing a 35% increase over 2024 levels. Within this landscape, HealthTech has emerged alongside AI and SaaS as a primary vertical for investment, attracting over 143 unique investors from around the globe.The rise of growth-stage capital, exemplified by the €130 million Big Pi Growth fund, has begun to address the historical "growth gap," allowing promising Greek ventures to scale their operations internationally while maintaining significant R&D and operational bases within the country.
This report identifies twenty future leaders, startups, spin-offs and visionary researchers, who are currently defining the frontiers of Greek healthtech and medtech.
20 Future Estonian HealthTech and MedTech Leaders
The emergence of Estonia as a preeminent global centre for health technology and medical engineering is a phenomenon predicated on the strategic synthesis of high-fidelity genomic data, a sophisticated digital identity infrastructure and a robust entrepreneurial ecosystem that prioritises clinical validation alongside technological scalability.
The transition from traditional reactive medical models, often characterised as "sick-care", toward a proactive, personalised, and predictive health economy is driven by a cohort of leaders who bridge the gap between academic rigour and commercial viability.
As the Estonian healthtech sector moves toward its "Vision 2035," which anticipates a high-density environment of science-based startups and a significant increase in healthy life years for the population, twenty specific individuals have surfaced as the architects of this transformation.
This report provides an analysis of these twenty future leaders, their technical contributions and the strategic implications of their work for the global healthcare landscape.
20 Future Czech HealthTech and MedTech Leaders
The healthcare technology and medical device sectors in the Czech Republic have reached a critical inflection point in 2026, transitioning from a regional innovation hub into a sophisticated global contender.
This evolution is defined by a shift in capital allocation strategies, moving away from fragmented, early-stage experimentation toward a disciplined focus on profitability, clinical validation and scalable business models. As of early 2026, the European healthtech market, valued at approximately $96.68 billion, is navigating a period of strategic evolution influenced by a reorientation of investor priorities. Within this context, the Czech ecosystem, centred largely in the innovation corridors of Prague and Brno, has distinguished itself through a high concentration of deep tech expertise, robust academic spin-off frameworks, and a successful navigation of the rigorous European Medical Device Regulation (MDR).
The resilience of the Czech sector is evidenced by its ability to secure significant funding rounds despite a 7.7% year-on-year decline in total investment for Czech founded startups in 2025, which totalled approximately €540 million. Notably, the healthtech vertical remained a cornerstone of this activity, with high-conviction "mega-deals" and strategic pre-seed rounds signaling a maturation of the ecosystem.
This report identifies and analyses 20 pivotal leaders whose vision and technical execution are shaping the future of Czech healthtech and medtech, categorised by their impact on diagnostic intelligence, chronic disease management, advanced biotechnology and the burgeoning field of digital resilience.
20 Future Portuguese HealthTech and MedTech Leaders
The Portuguese healthtech and medtech landscape has reached a state of systemic maturity, transitioning from a localized cluster of academic spin-offs to a formidable international player in precision medicine, digital surgery, and biotechnology. By the mid-2020s, the national startup ecosystem recorded a 16% increase in active ventures, totalling over 4,700 companies, of which nearly 70% were founded within the preceding five-year window.
This acceleration is not merely numerical but represents a qualitative shift toward high-complexity "Deep Tech" and "Fusion Research," where the barriers between laboratory investigation and clinical implementation are systematically dismantled.
The influx of venture capital, reaching €886 million in 2024, a 55% increase over previous years, has provided the necessary liquidity for Portuguese leaders to compete on a global stage, particularly in AI-driven care and sustainable biotechnology.
20 Future Swiss HealthTech and MedTech Leaders
The Swiss life sciences sector has entered a transformative era in 2025 and 2026, characterised by a fundamental shift from traditional pharmaceutical dominance toward a highly integrated "deep tech" health ecosystem. This evolution is underpinned by a robust venture capital environment that saw high-tech investments rise by 23.9% to CHF 2.9 billion in 2025, despite broader global economic uncertainties and sluggish growth in export-oriented industries. Within this capital influx, the medtech and biotech sectors have emerged as the most resilient pillars, driven by the unparalleled efficiency of the Swiss academic engine, specifically the Swiss Federal Institutes of Technology in Zurich (ETH Zurich) and Lausanne (EPFL).
The record-breaking creation of 46 new ventures from ETH Zurich in 2025 serves as a testament to the maturation of the university spin-off model. This model is no longer merely about patent licensing but represents a comprehensive institutional commitment to commercializing research through formalized pathways like the ETH Pioneer Fellowship and the newly launched "Express Licensing" procedure. This procedure, which provides a standardized, negotiation-free license within six to eight weeks in exchange for a modest 2% equity stake, has drastically reduced the barriers to entry for scientific founders. Consequently, Swiss academic institutions now rank among the top ten globally for spin-off value creation, outperforming larger economies on a per-capita basis.
However, the ecosystem faces a structural "late-stage gap," where approximately 96% of late-stage capital originates from international sources. This has necessitated a strategic focus on global expansion, particularly into the United States market. The Venture Leaders Medtech program, which selects the "Swiss National Startup Team" for an intensive roadshow in Boston, serves as a critical bridge for these 20 leaders as they transition from pre-clinical prototypes to market-ready clinical solutions.
20 Future Belgian HealthTech and MedTech Leaders
The Belgian healthcare innovation landscape has undergone a tectonic shift over the last decade, evolving from a traditional pharmaceutical stronghold into a globally recognised "Health and Biotech Valley". This maturation is not merely a product of historical legacy but the result of a deliberate, multi-layered strategy involving institutional catalysts, regional specialisation and a robust venture capital framework that prioritises deeptech inter-disciplinarity
The convergence of biotechnology, medical devices (MedTech) and digital health solutions has created an environment where the boundaries between hardware, software and biology are increasingly porous.
20 Future Norwegian HealthTech and MedTech Leaders
The Norwegian life sciences landscape is currently undergoing a systemic transition, evolving from a research-intensive academic environment into a globally integrated commercial powerhouse. This metamorphosis is facilitated by a unique confluence of high-trust public health data, a robust sovereign wealth environment and a maturing infrastructure of specialised clusters such as Norway Health Tech, the Oslo Cancer Cluster and Aleap. As the global healthcare market increasingly demands precision medicine, decentralised care models and AI-augmented diagnostics, Norway has positioned itself as a "forerunner" region.
This status is characterised by a "human scale" that allows for rapid testing and validation of sophisticated technologies within a public healthcare system, often referred to under the regional identity of "HealthFjords".
The following report provides an analysis of twenty future leaders within this sector, the technological breakthroughs they oversee and the second-order socio-economic impacts of their work on the global stage.
20 Future Romanian HealthTech and MedTech Leaders
The technological landscape of Romania has experienced a seismic shift between the fiscal years of 2024 and 2026, transitioning from a secondary outsourcing destination into a primary forge for high-valuation HealthTech and MedTech intellectual property. This metamorphosis is not merely anecdotal; it is substantiated by a radical escalation in capital inflow and a strategic pivot toward "Born Global" enterprises that prioritise international scalability from their inception.
The year 2025 stands as a historical inflection point for the region, where a single landmark financing event, the $165 Million Series C round for the robotics firm Dexory, nearly equaled the entire venture capital output of the Romanian ecosystem in 2024. This surge in liquidity, backed by global institutional heavyweights such as Atomico, Eurazeo and Lakestar, signals that the operational ceiling for Romanian-founded companies has been permanently elevated, transitioning the narrative from a regional hub to a consistent producer of global category leaders in medical and assistive technologies.
The maturation of the sector is further evidenced by the increasing density of DeepTech and AI-native startups. By early 2026, the Romania Tech Startup Association (ROTSA) and accelerators like Techcelerator had mapped over 100 artificial intelligence startups with Romanian roots, many of which are dedicated to solving high-complexity problems in oncology, radiotherapy, microbiome analysis and feline longevity.
This report analyses 20 such leaders, representing a mix of high-growth scale-ups, innovative pre-seed ventures and visionary individuals who are redefining the intersection of healthcare and technology.
20 Future Finnish HealthTech and MedTech Leaders
The Finnish healthcare technology sector has undergone a profound transformation, evolving from a niche engineering discipline into the nation's most significant high-tech export industry. By early 2026, the sector has established itself as a global paradigm for how a small, digitally advanced nation can leverage longitudinal data and institutional trust to solve systemic global healthcare challenges.
This transition is anchored in a unique structural advantage: a century of digitised health data and a legislative framework that permits the ethical, secondary use of this data for research and development. As global healthcare systems grapple with acute staffing shortages, aging populations, and rising costs, the Finnish ecosystem offers a blueprint for data-driven, human-centric innovation.
20 Future Irish HealthTech and MedTech Leaders
The Republic of Ireland has established a formidable global position within the medical technology and digital health sectors, characterised by a unique synthesis of indigenous entrepreneurial agility and high-density multinational presence.
As of 2025, the sector generates approximately €16 Billion in annual exports, representing 14% of the nation’s total export economy. With over 700 life sciences and health technology firms, more than 400 of which are homegrown, Ireland has successfully leveraged its academic research infrastructure and favourable venture capital environment to become the largest employer of MedTech professionals per capita in Europe.
In 2024, the ecosystem reached a decade-high record in venture capital investment, securing €491.3 million across 89 deals, even as global life sciences funding experienced a dramatic contraction. This resilience is largely attributed to the maturing profile of the cluster, where late-stage and venture-growth deals now constitute 46% of total volume, reflecting a shift from speculative early-stage ventures to clinically validated, scalable platforms.
This report analyses the twenty leaders and organisations at the vanguard of this evolution, examining the technological mechanisms, leadership backgrounds and market dynamics that define the next wave of Irish healthcare innovation.
20 Future Polish HealthTech and MedTech Leaders
The Polish healthcare technology ecosystem has transitioned from a localised secondary market into a primary driver of European deep-tech innovation as of the first quarter of 2026. This transformation is underpinned by a structural shift from traditional software development to the application of advanced artificial intelligence, multimodal biological simulations, and high-precision medical hardware.
Currently, Poland hosts over 3,300 active startups, with the Warsaw and Kraków hubs serving as the principal gravity centers for venture activity and technical talent. The sector's expansion is validated by significant capital inflows; in 2025, venture capital investment reached approximately PLN 3.4 Billion (~EUR 800 Million) across 180 distinct transactions, a momentum that has rallied into the current fiscal year.
The institutional backbone of this growth is reinforced by the launch of "Future Tech Poland," a €350 Million fund-of-funds initiative spearheaded by the European Investment Fund (EIF) and Bank Gospodarstwa Krajowego (BGK).
This program provides critical liquidity for high-tech ventures at various stages of growth, emphasising the Polish government’s commitment to establishing the nation as a global tech hub and enhancing the competitiveness of the European Union’s fifth-largest economy. Within this fertile landscape, a cadre of twenty leaders and their respective organisations have emerged as the vanguard of the Polish HealthTech and MedTech renaissance.
20 Future Icelandic HealthTech and MedTech Leaders
The Icelandic healthcare technology (HealthTech) and medical device (MedTech) sectors have entered a period of unprecedented expansion, transitioning from a localised research infrastructure into a globally competitive innovation hub. This evolution is fundamentally rooted in the unique intersection of Iceland’s high-fidelity genomic data, a single-payer nationalised healthcare system, and a robust academic-clinical nexus centered at the University of Iceland and Landspítali University Hospital.
Historically known for pioneering work in population genetics through deCODE genetics, the contemporary Icelandic ecosystem has matured, giving rise to a new generation of leaders who are leveraging artificial intelligence (AI), advanced biotechnology and digital health platforms to address global medical challenges.
The emergence of Kerecis as the nation’s first "unicorn", achieving a $1.3 Billion valuation upon its acquisition by Coloplast, serves as a definitive proof-of-concept for the Icelandic model of innovation, catalysing increased venture capital interest and proving that a small-market environment can produce world-leading medical solutions.
20 Future Italian HealthTech and MedTech Leaders
The Italian life sciences ecosystem has entered a period of profound structural transformation, transitioning from a cluster of high-quality specialised manufacturers into a primary engine of European medical innovation. Historically recognised as the fourth-largest medical device market in Europe, Italy is now characterised by a surge in venture capital activity, strategic international partnerships and a regulatory environment that is increasingly favourable to high-growth scale-ups.
The convergence of the National Recovery and Resilience Plan (PNRR), which allocates significant capital to healthcare digitalisation and the emergence of institutional investors such as CDP Venture Capital and Angelini Ventures, has created a fertile ground for "soonicorns" positioned for high-value exits or massive fundraising rounds.
As of early 2026, the Italian market size for medical devices and technology stands at approximately $13.04 Billion, with a robust local production value exceeding $10.3 Billion. However, the real story lies in the shift toward "intelligent" healthcare: surgical robotics, gene therapies, neurotechnology, and AI-driven preventative platforms.
This report identifies 20 companies that represent the vanguard of this shift, each demonstrating the technical defensibility and commercial traction required to attract global strategic acquirers and institutional growth capital.
20 Future Spanish HealthTech and MedTech Leaders
The Spanish healthcare technology landscape entering 2026 is defined by a transition from a nascent, fragmented ecosystem into a phase of "industrial maturity". This evolution is characterised by a disciplined approach to capital allocation, a focus on measurable clinical outcomes and the emergence of regional hubs that are increasingly competitive on a global scale.
While historically overshadowed by the larger hubs of London, Paris and Berlin, the Spanish market, led by Catalonia, Madrid, and Valencia, has demonstrated a unique resilience and a high capacity for scientific production, particularly in biotechnology and advanced therapies. In 2025, the sector reached a milestone with €517 Million invested in health startups and scale-ups in Catalonia alone, reflecting a 43% year-on-year increase and signalling a robust resurgence in investor confidence following the post-pandemic correction.
This maturity is further underscored by the shifting patterns of funding. While the absolute number of deals may have stabilised or slightly declined in certain subsectors, the average ticket size has increased dramatically. In 2025, venture capital remained the primary engine of growth, yet the market saw the return of "mega-deals" and concentrated late-stage rounds, where nearly 47% of total capital was raised by just three standout operations. This concentration suggests that investors are no longer making speculative bets across a wide range of early-stage ventures but are instead doubling down on "soonicorns" that have successfully built "compliance moats" around their core technologies, particularly in response to the full enforcement of the EU AI Act in March 2026.
The strategic importance of the Spanish ecosystem is also tied to the broader European goal of "strategic autonomy" in health and life sciences. With the pharmaceutical industry committing to €9 Billion in investments in Spain between 2023 and 2025, the synergy between established multinational corporations and agile technology startups has become a critical driver for clinical research and production leadership. Spain now ranks first in Europe in the percentage of high-impact scientific articles and fourth in Europe for the number of active clinical trials, providing a fertile ground for companies focused on clinical trial optimisation and data-driven drug discovery.
20 Future Swedish HealthTech and MedTech Leaders
The Swedish medical technology and digital health ecosystem is currently navigating a pivotal transition from early-stage innovation toward global commercial scale. As of 2025, the sector is defined by a robust convergence of computational biology, artificial intelligence, and decentralised care models, positioning Sweden as a primary engine of the European "TechBio" movement.
The industry comprises over 2,100 medtech companies, which, alongside the broader life science sector, generated approximately $46.8 Billion in net turnover in 2022, a 54 % increase compared to 2014. This growth is supported by a highly specialised workforce that has expanded by 18% since 2019, reflecting the sector's resilience and its role as the second-largest export sector in Sweden, accounting for nearly 10 percent of total product exports.
The national strategic framework is anchored by "Vision for eHealth 2025," an ambitious government initiative aimed at making Sweden the world leader in leveraging digitalization to provide equitable, high-quality healthcare.
This vision is underpinned by substantial regional investments in IT infrastructure, totalling approximately $1.22 Billion annually.Furthermore, the decentralisation of care is accelerating, with the home healthcare market projected to reach $8.1 Billion by 2030, representing a compound annual growth rate (CAGR) of 10.3 percent from 2025 to 2030. While digital services currently represent the largest revenue segment, equipment and remote monitoring technologies are identified as the most profitable and fastest-growing categories.
20 Future Austrian HealthTech and MedTech Leaders
The European healthcare technology and medical technology sectors enter 2026 at a profound inflection point, moving from a period of post-pandemic recalibration to what market analysts describe as an era of "industrial maturity". Within this broader continental shift, Austria has emerged as a particularly disciplined and resilient hub for innovation.
While the speculative fragmentation of the early 2020s led to detached valuations, the current vintage of Austrian startups is defined by a rigorous focus on unit economics, clinical validation and regulatory foresight.
This report provides an analysis of the Austrian healthtech and medtech ecosystem, identifying twenty specific companies that are uniquely positioned for high-growth trajectories, significant venture capital infusions, or strategic acquisition by global incumbents.
20 Future Danish HealthTech and MedTech Leaders
The Danish healthtech and medtech sectors have entered 2026 as the primary engine of Northern Europe’s innovation economy, characterised by a transition from the speculative fragmentation of the early 2020s toward a period of profound industrial maturity.
This evolution is underpinned by a robust national infrastructure, most notably the Medicon Valley cluster, which spans Eastern Denmark and Southern Sweden and houses one of the most concentrated life science ecosystems globally.
In 2026, the sector is defined by a rigorous focus on "Industrialisation," where venture capital and private equity firms have moved beyond "growth at all costs" metrics toward the "Rule of 40 + Data," prioritising assets that balance scale with unit-level profitability and defensible, proprietary clinical datasets.
The institutional backbone of this ecosystem has been further fortified by massive capital injections. The Novo Nordisk Foundation’s allocation of DKK 5.5 billion (approximately EUR 736 million) to the BioInnovation Institute (BII) through 2035 represents a generational commitment to scaling deep-tech and life science startups into global category leaders.
This funding frame specifically prioritises the intersection of biotechnology with artificial intelligence and quantum technologies, fields where Denmark maintains a disproportionate competitive advantage due to its unique health data infrastructure.
As of early 2026, Denmark leads Europe in digital public services and research and development (R&D) intensity, facilitated by the universal application of the personal identifier (CPR number) which allows for cradle-to-grave longitudinal health data linkage—a critical asset for AI-driven diagnostic and therapeutic platforms.
20 Future Dutch HealthTech and MedTech Leaders
The Dutch healthcare technology and medical technology landscape entering 2026 stands at a profound inflection point, characterised by a definitive transition from the speculative fragmentation of the early 2020s toward a disciplined era of industrial maturity.
Following a period of structural recalibration in 2024 and a tentative recovery in 2025, the market is currently experiencing a robust, albeit structurally transformed, resurgence in capital deployment and mergers and acquisitions. The defining thesis for 2026 is the concept of "Industrialisation," which signifies a departure from the "growth at all costs" paradigm that defined the Zero Interest Rate Policy era. In this current cycle, the cost of capital remains elevated, forcing a rigorous recalibration of investment criteria toward unit economics and measurable clinical impact.
The Netherlands has positioned itself as a top-tier hub for innovation, yet it faces a rapidly changing global environment where ambition alone is no longer sufficient to maintain a leading position. Deeptech remains the Dutch ecosystem's powerhouse, producing 41% of all scaleups and attracting the majority of venture capital in 2025.
However, a significant "AI Paradox" persists; despite having the highest density of AI talent in Europe, the Dutch conversion rate of AI startups to scaleup status is only a quarter of the rate seen in the United States. This gap is a primary focus of national strategic initiatives aimed at securing the country's long-term growth through 2035.
Nelson Advisors > European MedTech and HealthTech Investment Banking
Nelson Advisors specialise in Mergers and Acquisitions, Partnerships and Investments for Digital Health, HealthTech, Health IT, Consumer HealthTech, Healthcare Cybersecurity, Healthcare AI companies. www.nelsonadvisors.co.uk
Nelson Advisors regularly publish Thought Leadership articles covering market insights, trends, analysis & predictions @ https://www.healthcare.digital
Nelson Advisors publish Europe’s leading HealthTech and MedTech M&A Newsletter every week, subscribe today! https://lnkd.in/e5hTp_xb
Nelson Advisors pride ourselves on our DNA as ‘Founders advising Founders.’ We partner with entrepreneurs, boards and investors to maximise shareholder value and investment returns. www.nelsonadvisors.co.uk
#NelsonAdvisors #HealthTech #DigitalHealth #HealthIT #Cybersecurity #HealthcareAI #ConsumerHealthTech #Mergers #Acquisitions #Partnerships #Growth #Strategy #NHS #UK #Europe #USA #VentureCapital #PrivateEquity #Founders #SeriesA #SeriesB #Founders #SellSide #TechAssets #Fundraising #BuildBuyPartner #GoToMarket #PharmaTech #BioTech #Genomics #MedTech
Nelson Advisors LLP
Hale House, 76-78 Portland Place, Marylebone, London, W1B 1NT
Meet Nelson Advisors @ 2026 Events
Digital Health Rewired > March 2026 > Birmingham, UK
NHS ConfedExpo > June 2026 > Manchester, UK
HLTH Europe > June 2026, Amsterdam, Netherlands
HIMSS AI in Healthcare > July 2026, New York, USA
Bits & Pretzels > September 2026, Munich, Germany
World Health Summit 2026 > October 2026, Berlin, Germany
HealthInvestor Healthcare Summit > October 2026, London, UK
HLTH USA 2026 > October 2026, USA
Barclays Health Elevate > October 2026, London, UK
Web Summit 2026 > November 2026, Lisbon, Portugal
MEDICA 2026 > November 2026, Düsseldorf, Germany
Venture Capital World Summit > December 2026 Toronto, Canada
Comments